Skip to main content
. 2019 Aug 28;8(5):227–245. doi: 10.1159/000502229

Table 1.

Parameters to be evaluated at baseline and at each control visit

Parameters to be evaluated
Clinical data Weight, appetite, fatigue, diarrhoea, skin manifestations, patient's diary on side effects and/or symptoms

Blood tests TSH, fT4 (thyroglobulin, Tg antibodies at periodical intervals) Electrolytes (Ca, Na, K, Mg) Full blood count ALT, ALP, GGT Glucose, total HDL, LDL cholesterol, triglycerides

Cardiac parameters ECG (QTc interval) Blood pressure

Imaging Whole-body imaging (CT scan with contrast medium and/or MRI and/or18-FDG-PET/CT scan) (first visit, then periodical evaluation metastatic sites) Bone scintigraphy (optional)